Share on

Global Rubella Vaccine Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By End User (Pediatric Rubella Vaccine, Adult Rubella Vaccine & Traveller Rubella Vaccine) & Region - Industry Forecasts (2023 to 2028)

Published: March, 2023
ID: 6176
Pages: 175
Formats: report pdf report excel report power bi report ppt

Rubella Vaccine (Human Diploid Cell) Market Size (2023 to 2028)

As per our report, the global rubella vaccine market is anticipated to be worth USD 254.27 Million by 2028 from USD 194.55 in 2023, growing at a CAGR of 5.50% from 2023 to 2028.

Rubella is also known as three-day measles. It is an infection which is caused by the rubella virus. Rubella is a viral and contagious infection that profoundly affects children and is infected due to the transfer of airborne drops of the transmitted individual through sneezing and coughing. The person who suffers from rubella must face many consequences, such as cough, rash, fever, headache, and many complications, such as viral infection resulting in death or congenital disability known as congenital rubella syndrome. The virus multiplies in the respiratory tract and is transferred to others via respiratory secretion by aerosolized droplets in a closed sections like schools and offices. This disease's symptoms appear 10-12 days after the infection, more likely fever. Rubella is prevented through the MMR vaccine, protecting against three diseases: measles, mumps, and rubella. According to the recommendation of the CDC, children between 12 and 15 months are to be given the first dose, and between 4 and 6 years old must be given the second dose of the vaccine. As far as teenagers and adults are concerned, they are supposed to be up to date on the MMR vaccine.


The rubella vaccine is expected to gain a large market in the coming years as the disease has been proven only by vaccination, and no other specific treatment is available.

The global rubella vaccine market is expected to have high market growth during the forecast period due to government and non-government activities. Disease indications in the vaccine market include rotavirus, hepatitis, polio, varicella, meningococcal disease, MMR, Human Papilloma Virus (HPV) infection, influenza, pneumococcal disease, Diphtheria, Tetanus and Pertussis, and others. In addition, the increasing incidence of pneumococcal infections propels the growth of the rubella vaccine market. Furthermore, due to the global support from WHO and other NGO partners, which have rightly helped in extensive immunization coverage and advanced immunization, the global rubella vaccine market is anticipated to be profitably driven over the forecast period. This is because, in every 1,000 births, four babies were born with congenital rubella syndrome (CRS) before the introduction of the vaccine, which afterward showed, 97% efficacy even with the single dose people, leading to the recommendation of national use of routine rubella vaccination in children by WHO since 1980. This resulted in the introduction of CVR in their immunization package of 152 countries out of 194.

YOY rise in the incidence of rubella is propelling the market growth.

Increasing incidence of rubella infection worldwide, nearly 100000 infected persons are affected by rubella annually. Therefore, it is solely leveraging the growth of the market. According to WHO recommendations, implementing a top-notch monitoring system is one of the primary strategies for achieving rubella elimination. Today, most nations in the Americas, Europe, and Western Pacific Region have monitoring systems for rubella, rubella in pregnancy, and congenital rubella syndrome. The government and non-government agencies are giving funds for rubella vaccine developments. Unvaccinated people are suffering from rubella in the majority. The initiatives of government authority and increasing the success rate of vaccination schemes on the government initiative of each country. The Asia Pacific is creating an awareness program and campaigns to prevent the disease from infection. The robust regulations and patient safety are anticipated for the market's growth.

The growth of the rubella vaccine market is also driven by the high prevalence of CRS in low- and middle-income countries such as India, China, Vietnam, and many other parts of Africa, primarily due to the defects found in structural heart for 80% of cases, 60% of cases with ocular signs of retinitis pigmentosa, glaucoma, and cataracts, and almost 40% diagnosed cases with hearing impairment, which was all suffered mainly by 25% of children under two years of age, who even suffered death. Therefore, the countries realized and reached a common conclusion the only way to overcome the problem was high vaccination coverage, initiating nationwide serological surveys. Furthermore, the market for measles, mumps, and rubella vaccines is expanding because of efforts by vaccine producers to collaborate with groups like UNICEF, WHO, and GAVI Alliance to enhance these organizations' immunization programs. These collaborative endeavors make reaching broad populations feasible, notably in impoverished and developing nations. This highlights the expansion of the market for measles, mumps, and rubella vaccinations, together with government measures for the effectiveness of immunization programmers since Measles is one of the top causes of infant mortality in developing and developing nations. In addition, increasing air pollution due to industrialization leads to a rise in airborne diseases worldwide, which is expected to fuel the market demand.


Vaccine-related side effects could be a major factor restraining the growth of the measles, mumps, and rubella vaccines markets, like the non-viral meningitis outbreak in Japan in 1998 and other harmful side effects. The strict manufacturing and approval criteria, high single dose cost, and high incidence of pneumococcal infections will further restrict the Rubella vaccine market. In addition, the side effect of vaccination and the high cost of vaccine production restrains the vaccine market. A limited number of vaccines, precise manufacturing, and the gap between demand and supply during disease outbreaks are the other factors that hamper the market's growth.

Impact of COVID-19 on the global rubella vaccine market:

The outbreak began in March 2020 and continued for over a year. The lockdowns and quarantines resulted from the coronavirus outbreak in China. Many businesses have suffered losses. There was a rise in the unemployment rate as more deaths were reported. The financial situation has deteriorated due to the unexpected increase in patients and the severe shortage of hospital resources. The market for the rubella vaccine had a negative impact of the covid-19 virus on the global market since the priority shift and rise in vaccination against COVID-19 slowed the pace of rubella vaccination. Moreover, the inherent disadvantages of constructing the rubella vaccine using human diploid cell technology, like high selectivity and low yield, are expected to limit the market growth.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

By End User and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa


This research report on the global rubella vaccine market has been segmented based on the end-user and region.

Rubella Vaccine Market – By Type:

  • Monovalent Formulation
  • Measles-Rubella Vaccine
  • Measles, Mumps, Rubella Vaccine
  • Measles Mumps Rubella Varicella Vaccine

The measles, mumps, and rubella vaccine MMR held the largest share of the market in 2022 and is predicted to continue dominating the market throughout the forecast period due to the rising cases of these diseases. In addition, they reported outbursts of the disease in many local areas. According to WHO statistics, more than 140,000 people died from measles in 2018. The dominance of this segment is also driven by the rising cases of chickenpox and the efficiency of the vaccine in protecting against diseases. For instance, more than 95% of American adults have had chickenpox, and about 4,000,000 people get chickenpox every year. 

Rubella Vaccine Market – By End User:

  • Pediatric
  • Adult
  • Traveler

Based on the end-user, the pediatric segment is estimated to have the highest share of the rubella vaccine market during the forecast period. The growth of this pediatric rubella vaccine is due to growing occurrences of rubella affecting children. Pediatric vaccines are more effective than adults; these are given in two doses. It protects the child from potentially serious illnesses, measles and mumps. Furthermore, it stops the child from spreading the disease to a pregnant woman, whose fetus can suffer fatal birth problems or develop severe deformities if the mother contracts the disease. In addition, the youngster won't develop a fever or rash from rubella.

The adult rubella vaccine segment is foreseen to dominate the market since the adults are required to be up to date on MMR vaccinations, with either 1, 2, or both doses, until the adults have already had the presumptive evidence of immunity to measles, mumps, and rubella. Generally, only one dose of the MMR vaccine is sufficient for most adults.

Rubella Vaccine Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Regionally, the North American rubella vaccine market is forecasted to account for the largest share of the global rubella vaccine market, followed by Europe and the Asia Pacific during the forecast period. North America is majorly driven by various steps taken by the government for different types of vaccines like HPV and Influenza. Also, growing awareness about the disease and vaccination is likely to accelerate the growth of this region.

The European rubella vaccine market is expected to occupy the second-largest global market share during the forecast period. Soaring governmental concentration in developing rubella vaccines and continuing research and development for vaccine advancements are boosting the market growth. However, the cost of these vaccines and the low yield hamper the market growth.

The Asia-Pacific rubella vaccine market is expected to grow with the highest CAGR value during the forecast. The growth is due to generating of awareness programs and campaigns to prevent the disease from spreading. Also, the market is expected to grow up due to robust regulations and patient safety.

The rubella vaccine market in the Latin American region is expected to show substantial growth in the rubella vaccine market during the forecast period. The low cost of the vaccines and the happening research and development activities for the advancement of rubella vaccines are estimated to offer profitable growth.

At the same time, the Middle East & African rubella vaccine market is also expected to showcase the robust growth of the rubella vaccine market during the forecast period. Growing government concentration on rubella vaccination is escalating market growth. Moreover, the outbreak continues in Africa as children of age five are most affected.


The most promising companies leading the Global Rubella Vaccine Market profiled in this report are Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., Johnson & Johnson Pvt. Ltd., MedImmune LLC, Bavarian Nordic A/S, Novartis International AG, China National Biotec Group Comp. Ltd., JC Medical, and Berna Biotech (Crucell).


  • In Oct 2022, the Syrian Ministry of Health in Vaccine Alliance launched a national 10-day vaccination campaign against poliomyelitis, with the support of UNICEF, WHO, and Gavi, to vaccinate 2.4 million children under the age of 5 in all Syrian governorates, mainly targeting northeast Syria with more than 28,000 children under informal settlements.
  • In June 2022, GSK plc. announced the improvement of active immunization by FDA to prevent measles, mumps, and rubella in children 12 months and older.
  • In May 2020, Merck acquired Themis, which has high growth in vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector.
  • In October 2019, Enesi Pharma, an innovative pharmaceutical company, produced a solid-dose drug-device vaccine product and received funding from the Bill & Melinda Gates Foundation to develop stable-dose vaccines for measles and rubella.

Please wait. . . . Your request is being processed


How much is the global rubella vaccine market going to be worth by 2028?

As per our research report, the global rubella vaccine market size is projected to be USD 254.27 Million by 2028. 

At What CAGR, the global rubella vaccine market is expected to grow from 2023 to 2028?

The global rubella vaccine market is estimated to grow at a CAGR of 5.50% from 2023 to 2028. 

Does this report include the impact of COVID-19 on the rubella vaccine market ?

Yes, we have studied and included the COVID-19 impact on the global rubella vaccine market in this report. 

Which region is anticipated to witness considerable growth in the rubella vaccine market ?

Geographically, the APAC rubella vaccine market is predicted to have the fastest growth rate in the global market from 2023 to 2028. 

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample